About us > Dr Paul Conway
Dr Paul Conway
BHlthSci, GradDipHlthSci, MBBS (Hons), FRANZCR
Radiation Oncologist
Dr Paul Conway provides precision, patient-centred care across both cancer treatment and low-dose radiotherapy for joint and tendon pain — a level of care he would want for his own family, backed by advanced training in both fields.
Quick Scroll
Clinical Expertise
Dr Paul Conway accepts referrals for all cancer types and for non-malignant conditions
with a special clinical interest in:
Precision Cancer Care
Enquire Today
Precision Joint Care
Free Suitability Check
Dr Paul Conway
Biography
Training & credentials
Paul completed his MBBS with First Class Honours at the University of Queensland in 2013, training at the Royal Brisbane and Women’s Hospital, Alfred Health, and Peter MacCallum Cancer Centre before becoming a Fellow of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 2021. A two-year fellowship under Dr Pat Bowden gave him direct experience across more than 250 supervised courses of stereotactic radiotherapy for oligometastatic disease. Dr Conway now collaborates with Dr Pat Bowden, leveraging their combined expertise to benefit patients. He has studied Proton Beam Therapy in Japan and is trained and credentialed in the CyberKnife stereotactic radiosurgery system.
Precision cancer care
Paul treats the full range of cancers, with particular focus on urologic cancers, particularly prostate cancer, alongside gastrointestinal, breast, lung, CNS and oligometastatic disease. He is one of a small number of Australian radiation oncologists trained and credentialed on the CyberKnife system, a robotic radiosurgery platform delivering sub-millimetre precision with real-time tumour tracking, and in 2025 treated Australia’s first CyberKnife prostate cancer patient at 5D Clinics Melbourne. Dr Conway has a keen interest in incorporating advanced technologies in providing care for his patients. He is currently incorporating next-generation dynamic imaging with the latest Quadra PET/CT technology for more precise radiotherapy planning and treatment.
Precision joint care
Alongside his oncology practice, Paul completed postgraduate studies in musculoskeletal management through the University of Otago, covering joint pathology, biomechanics, pain mechanisms and evidence-based clinical decision-making. He furthered this through the Radiotherapy Academy for Benign Conditions (RT-ABC), an international program focused on patient selection, dosing and the evidence base for low-dose radiotherapy in non-malignant conditions. He now leads Pinpoint’s low-dose radiotherapy service for osteoarthritis, plantar fasciitis, tendinopathies and related conditions.
Research & academic roles
Dr Conway’s current research interests centre on advancements in imaging and treatment technologies. His research includes dynamic PET imaging and novel tracer technology to improve disease detection and characterisation for precise treatment planning. He is actively involved in the follow-up of the TRANSFORM trial, led by Dr Pat Bowden, which is the largest study of its kind in the world investigating the use of stereotactic radiotherapy for treating oligometastatic prostate cancer. He serves as the Radiation Oncology representative on the Medical Advisory Committee at John Fawkner Private Hospital and is an active member of the Trans-Tasman Radiation Oncology Group (TROG).
Where Paul practises
Paul consults and treats across Icon Cancer Centre sites in Melbourne and Canberra, as well as at 5D Clinics Melbourne for CyberKnife treatment, with accommodation available for patients travelling from interstate or abroad.
Research
Near-Universal PSA response to stereotactic radiotherapy provides biological support for long axial field of view PSMA-PET/CT in identifying clinically relevant disease in biochemical recurrence of prostate cancer
Conway R, Callahan J, Kanal S, Conway P, Hicks RJ.
APCC Conference Presentation, 2026
High Detection Rates for Prostate-specific Membrane Antigen-avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography
Thomas S, Callahan J, Conway P, Moon D, Morgan H, Ingbritsen J, Munro M, Ware RE, Dundee P, Hicks RJ.
Eur Urol Open Sci. 2024 Dec 7;71:49-56.
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
See AW, Conway P, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Pranavan G, Peters J, Smyth LML, Gwini SM, McKenzie DP, Bowden P.
Int J Cancer. 2024 Oct 1;155(7):1248-1256.
Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study.
Rogé M, Bowden P, Conway P, Franzese C, Scorsetti M, Seront E, Blanchard P, Terlizzi M, Khalifa J, Pasquier C, Shick U, Siva S, Paul J, Supiot S.
Clin Transl Radiat Oncol. 2025 Mar 10;52:100944.
Radiation necrosis and therapeutic outcomes in patients treated with linear accelerator-based hypofractionated stereotactic radiosurgery for intact brain metastases.
Zhang Q, Hamilton D, Conway P, Xie SJ, Haghighi N, Lasocki A.
J Med Imaging Radiat Oncol. 2023 Apr;67(3):308-319.
Oesophageal cancer treatment patterns, timeliness of care and outcomes in the Loddon Mallee region of Victoria: a retrospective cohort study.
Conway P, Leach M, Tejani N, Robinson A, Shethia Y, Solo I.
J Med Imaging Radiat Oncol. 2021 Apr;65(2):242-250.
